Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...
William Blair analyst Sami Corwin reiterated a Hold rating on Bluebird Bio (BLUE – Research Report) today. The company’s shares closed today at $0.36. Corwin covers the Healthcare sector, focusing ...
Bluebird Bio (BLUE) has been beaten down lately with too much selling pressure. While the stock has lost 22.8% over the past ...
SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...
Research analysts at StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE – Get Free Report) in a research ...
Bluebird Bio (BLUE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.66 per share a year ago. These figures are ...
Analysts estimate that bluebird bio will report an earnings per share (EPS) of $-0.37. Anticipation surrounds bluebird bio's announcement, with investors hoping to hear about both surpassing estimates ...
JP Morgan has recently reduced bluebird bio Inc (BLUE) stock to Neutral rating, as announced on August 15, 2024, according to Finviz. Earlier, on December 11, 2023, HSBC Securities had reduced the ...
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it partially adjourned its annual meeting of stockholders (“Annual Meeting”) on Wednesday ...